Management of Uncontrolled Stage 2 Hypertension on Lisinopril Monotherapy

Immediate Treatment Strategy

The American College of Cardiology and European Heart Society recommend adding a second antihypertensive agent from a different class rather than simply increasing the lisinopril dose for patients with blood pressure ≥160/100 mmHg, as this approach has been shown to reduce cardiovascular morbidity and mortality 1, 2, 3
The American Heart Association suggests that the most effective approach is to initiate combination therapy immediately, as patients with BP ≥160/100 mmHg should be promptly treated with upward medication adjustment 1, 3

The European Society of Cardiology recommends adding a thiazide-like diuretic (chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg) to the current lisinopril 20 mg, as this combination of an ACE inhibitor plus thiazide diuretic is a first-line, evidence-based approach that has demonstrated superior cardiovascular outcomes 2, 4, 5
The American College of Cardiology suggests that alternatively, adding a dihydropyridine calcium channel blocker (amlodipine 5-10 mg) to lisinopril 20 mg is equally effective and may be preferred if the patient has contraindications to diuretics or experiences metabolic side effects 2, 4

The European Heart Society recommends a target BP of <130/80 mmHg for patients with stage 2 hypertension to reduce cardiovascular risk 2, 3, 6
The American Heart Association suggests reassessing BP within 2-4 weeks after initiating combination therapy to evaluate response and check electrolytes and renal function (particularly important when adding a diuretic or ACE inhibitor) 1, 3
The European Society of Cardiology recommends achieving target BP within 3 months of treatment intensification 2, 7

The American College of Cardiology recommends confirming medication adherence, as non-adherence is a leading cause of apparent treatment resistance 7, 8
The European Heart Society suggests ruling out white-coat hypertension by obtaining home BP readings or 24-hour ambulatory BP monitoring, as office readings may overestimate true BP 1, 3
The American Heart Association recommends assessing for secondary hypertension if BP proves difficult to control, particularly looking for renal artery stenosis, primary aldosteronism, obstructive sleep apnea, or pheochromocytoma 6, 7

The European Society of Cardiology recommends implementing DASH or Mediterranean diet with sodium restriction to <2,300 mg/day 2, 6
The American Heart Association suggests recommending 150 minutes/week of moderate-intensity aerobic exercise plus resistance training 2-3 times weekly 2, 6
The European Heart Society recommends targeting weight reduction if BMI >25 kg/m², aiming for BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women) 2
The American College of Cardiology suggests limiting alcohol consumption to ≤2 drinks/day for men, ≤1 drink/day for women 2

The European Society of Cardiology recommends avoiding therapeutic inertia - failing to intensify therapy promptly when BP remains uncontrolled is a major cause of poor outcomes 7, 8
The American Heart Association suggests not combining two RAS blockers (ACE inhibitor + ARB) as this increases adverse effects without additional benefit 2, 4
The European Heart Society recommends monitoring for orthostatic hypotension, particularly in older patients or those with postural symptoms, when intensifying therapy 1, 3
The American College of Cardiology suggests not using beta-blockers as routine add-on therapy unless there are compelling indications (post-MI, heart failure, angina, or rate control) 2, 4